CN100436418C - 用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物 - Google Patents

用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物 Download PDF

Info

Publication number
CN100436418C
CN100436418C CNB988118955A CN98811895A CN100436418C CN 100436418 C CN100436418 C CN 100436418C CN B988118955 A CNB988118955 A CN B988118955A CN 98811895 A CN98811895 A CN 98811895A CN 100436418 C CN100436418 C CN 100436418C
Authority
CN
China
Prior art keywords
methyl
compound
fluoro
hydrogen
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988118955A
Other languages
English (en)
Chinese (zh)
Other versions
CN1281436A (zh
Inventor
格哈德·施佩尔
保罗·格罗斯
克劳斯·布伦德尔
加里·皮亚扎
里法特·帕姆克库
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
University of Arizona
Original Assignee
Cell Pathways Inc
OSI Pharmaceuticals LLC
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/989,353 external-priority patent/US5948779A/en
Application filed by Cell Pathways Inc, OSI Pharmaceuticals LLC, University of Arizona filed Critical Cell Pathways Inc
Publication of CN1281436A publication Critical patent/CN1281436A/zh
Application granted granted Critical
Publication of CN100436418C publication Critical patent/CN100436418C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNB988118955A 1997-12-12 1998-12-11 用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物 Expired - Fee Related CN100436418C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/989,353 1997-12-12
US08/989,353 US5948779A (en) 1997-12-12 1997-12-12 Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
US09/206,245 1998-12-07
US09/206,245 US6066634A (en) 1997-12-12 1998-12-07 Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia

Publications (2)

Publication Number Publication Date
CN1281436A CN1281436A (zh) 2001-01-24
CN100436418C true CN100436418C (zh) 2008-11-26

Family

ID=26901185

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988118955A Expired - Fee Related CN100436418C (zh) 1997-12-12 1998-12-11 用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物

Country Status (18)

Country Link
US (3) US6166053A (https=)
EP (1) EP1044187B1 (https=)
JP (1) JP4307719B2 (https=)
CN (1) CN100436418C (https=)
AT (1) ATE257152T1 (https=)
AU (1) AU752072B2 (https=)
BR (1) BR9813540A (https=)
CA (1) CA2314339C (https=)
CZ (1) CZ298826B6 (https=)
DE (1) DE69820908T2 (https=)
ES (1) ES2212383T3 (https=)
HU (1) HU227153B1 (https=)
IL (1) IL136603A0 (https=)
NO (1) NO317097B1 (https=)
NZ (1) NZ504958A (https=)
PL (1) PL196936B1 (https=)
TR (1) TR200001687T2 (https=)
WO (1) WO1999031065A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257152T1 (de) * 1997-12-12 2004-01-15 Osi Pharm Inc N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
JP2004500425A (ja) * 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2002067936A1 (en) * 2001-02-21 2002-09-06 Cell Pathways, Inc. Methods for treatment of inflammatory bowel disease
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US20030073740A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of lupus erythematosus
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
CN100398522C (zh) * 2003-08-20 2008-07-02 Irm责任有限公司 组织蛋白酶s的抑制剂
US6995622B2 (en) * 2004-01-09 2006-02-07 Robert Bosh Gmbh Frequency and/or phase compensated microelectromechanical oscillator
JP2008501407A (ja) 2004-06-02 2008-01-24 メリット ダイアモンド コーポレイション 装身具のための快適な内側およびその内側を備える装身具
CN1332930C (zh) * 2005-08-05 2007-08-22 中国科学院上海有机化学研究所 制备乙氰菊酯前体的方法
US8044048B2 (en) * 2006-01-04 2011-10-25 Southern Research Institute Derivatives of sulindac, use thereof and preparation thereof
WO2009022756A1 (ja) * 2007-08-13 2009-02-19 Katayama Chemical Industries Co., Ltd. 虚血性疾患の診断及び治療
WO2010053910A1 (en) * 2008-11-04 2010-05-14 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
JP2013501665A (ja) 2009-08-07 2013-01-17 オークランド ユニサービシズ リミテッド 道路から電気エネルギーを得る電気車両システム
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
JP7169008B2 (ja) 2018-04-26 2022-11-10 エーディーティー ファーマシューティカルズ，エルエルシー 抗がんインデン、インダン、アザインデン、アザインダン、医薬組成物および使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643959A (en) * 1991-03-08 1997-07-01 Cell Pathways, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
ATE257152T1 (de) * 1997-12-12 2004-01-15 Osi Pharm Inc N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia
US5948779A (en) * 1997-12-12 1999-09-07 Cell Pathways, Inc. Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643959A (en) * 1991-03-08 1997-07-01 Cell Pathways, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof

Also Published As

Publication number Publication date
US6610854B2 (en) 2003-08-26
CZ298826B6 (cs) 2008-02-20
US20030009033A1 (en) 2003-01-09
US6166053A (en) 2000-12-26
EP1044187B1 (en) 2004-01-02
NO20002972L (no) 2000-08-09
AU752072B2 (en) 2002-09-05
PL196936B1 (pl) 2008-02-29
JP4307719B2 (ja) 2009-08-05
EP1044187A1 (en) 2000-10-18
IL136603A0 (en) 2001-06-14
WO1999031065A1 (en) 1999-06-24
NO317097B1 (no) 2004-08-09
PL341151A1 (en) 2001-03-26
NO20002972D0 (no) 2000-06-09
US6426349B1 (en) 2002-07-30
NZ504958A (en) 2003-03-28
CZ20002157A3 (cs) 2000-10-11
HUP0100170A3 (en) 2001-12-28
HUP0100170A1 (hu) 2001-07-30
DE69820908D1 (de) 2004-02-05
CA2314339A1 (en) 1999-06-24
CN1281436A (zh) 2001-01-24
AU1498199A (en) 1999-07-05
BR9813540A (pt) 2000-10-10
ATE257152T1 (de) 2004-01-15
DE69820908T2 (de) 2004-12-23
JP2002508358A (ja) 2002-03-19
HU227153B1 (en) 2010-08-30
CA2314339C (en) 2009-09-08
TR200001687T2 (tr) 2000-10-23
ES2212383T3 (es) 2004-07-16

Similar Documents

Publication Publication Date Title
CN100436418C (zh) 用于治疗肿瘤的n-苄基-3-茚乙酰胺衍生物
US6211177B1 (en) Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
KR100592974B1 (ko) 종양 치료용 ｎ-벤질-3-인데닐아세트아미드 유도체
JP2001509810A (ja) Ｍｍｐインヒビターとしてのビス−スルホンアミドヒドロキサム酸
US7482369B2 (en) Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
JP2004529088A (ja) ＩｋＢキナーゼ（ＩＫＫ）のインヒビターを用いる炎症性および免疫疾患の処置法
JP2000514417A (ja) 置換ベンジリデンインデニルホルムアミド、アセタミドおよびプロピオンアミド
JPH11269140A (ja) 分化誘導剤
US6028116A (en) Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
US6369092B1 (en) Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6180629B1 (en) [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6486158B1 (en) [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
US6420410B1 (en) Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US20020028936A1 (en) 1,3-disubstituted indolin-2-ones for neoplasia
HK1030947B (en) N-benzyl-3-indenylacetamides derivatives for treating neoplasia
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
US6160003A (en) 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
RU2797694C2 (ru) О-аминогетероарилалкинилсодержащее соединение, способ его получения и его применение
JP4121268B2 (ja) イミダゾール誘導体、その製造法および用途
US6455703B2 (en) 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: OSI PHARMACEUTICAL CO.,LTD.

Free format text: FORMER OWNER: CELL PATHWAYS, INC.

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20040611

Address after: American Pennsylvania

Applicant after: Osi Pharm Inc.

Co-applicant after: The University of Arizona

Address before: American Pennsylvania

Applicant before: Cell Pathways, Inc.

Co-applicant before: The University of Arizona

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1030947

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081126

Termination date: 20121211